selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic synthetic vaccine particles (svp™) to a range of biologics for rare and serious diseases that require new treatment options. the company’s current proprietary pipeline includes svp-enabled enzyme, oncology and gene therapies. sel-212, the company’s lead candidate in phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. selecta’s sel-403 product candidate, a combination therapy consisting of svp-rapamycin and lmb-100, recently entered a phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. selecta’s proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat
Company profile
Ticker
RNAC
Exchange
Website
CEO
Carsten Brunn
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
SELECTA BIOSCIENCES INC
SEC CIK
Corporate docs
Subsidiaries
Selecta (RUS) LLC • Selecta Biosciences Security Corporation • Cartesian Bio, LLC ...
RNAC stock data
Latest filings (excl ownership)
8-K
Other Events
22 Apr 24
8-K
Regulation FD Disclosure
9 Apr 24
8-K
Departure of Directors or Certain Officers
1 Apr 24
8-K
Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split
28 Mar 24
8-K
Termination of a Material Definitive Agreement
14 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
7 Mar 24
8-K
Entry into a Material Definitive Agreement
5 Mar 24
DEFA14A
Additional proxy soliciting materials
14 Feb 24
DEF 14A
Definitive proxy
14 Feb 24
Transcripts
RNAC
Earnings call transcript
2023 Q2
17 Aug 23
RNAC
Earnings call transcript
2023 Q1
4 May 23
RNAC
Earnings call transcript
2022 Q4
2 Mar 23
RNAC
Earnings call transcript
2022 Q3
3 Nov 22
RNAC
Earnings call transcript
2022 Q2
6 Aug 22
RNAC
Earnings call transcript
2022 Q1
6 May 22
RNAC
Earnings call transcript
2021 Q4
10 Mar 22
RNAC
Earnings call transcript
2021 Q3
9 Nov 21
RNAC
Earnings call transcript
2021 Q2
12 Aug 21
RNAC
Earnings call transcript
2021 Q1
13 May 21
Latest ownership filings
3
Emily English
19 Apr 24
SC 13D/A
SPRINGER TIMOTHY A
12 Apr 24
4
Michael Singer
10 Apr 24
4
Murat Kalayoglu
10 Apr 24
4
TIMOTHY A SPRINGER
10 Apr 24
4
Christopher M Jewell
10 Apr 24
4
Milos Miljkovic
10 Apr 24
4
Metin Kurtoglu
10 Apr 24
SC 13D/A
Kalayoglu Murat
10 Apr 24
SC 13D/A
Singer Michael
10 Apr 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 80.98 mm | 80.98 mm | 80.98 mm | 80.98 mm | 80.98 mm | 80.98 mm |
Cash burn (monthly) | 11.34 mm | 2.79 mm | 4.36 mm | 4.88 mm | 3.07 mm | 3.31 mm |
Cash used (since last report) | 77.67 mm | 19.10 mm | 29.83 mm | 33.43 mm | 21.04 mm | 22.67 mm |
Cash remaining | 3.31 mm | 61.88 mm | 51.15 mm | 47.55 mm | 59.94 mm | 58.31 mm |
Runway (months of cash) | 0.3 | 22.2 | 11.7 | 9.7 | 19.5 | 17.6 |
Institutional ownership, Q3 2023
67.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 90 |
Opened positions | 8 |
Closed positions | 13 |
Increased positions | 21 |
Reduced positions | 29 |
13F shares | Current |
---|---|
Total value | 44.66 bn |
Total shares | 104.91 mm |
Total puts | 2.40 k |
Total calls | 15.70 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
Timothy A Springer | 36.85 mm | $40.17 mm |
Artal International S.C.A. | 10.21 mm | $12.76 mm |
Artal | 9.14 mm | $9.69 mm |
BLK Blackrock | 7.75 mm | $8.21 bn |
Vanguard | 7.19 mm | $7.62 bn |
Madison Avenue Partners | 4.01 mm | $4.25 bn |
Mangrove Partners Master Fund | 3.33 mm | $10.10 mm |
FMR | 2.57 mm | $2.72 bn |
Geode Capital Management | 2.38 mm | $2.53 bn |
Nantahala Capital Management | 2.20 mm | $2.33 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Apr 24 | Elizabeth Hoge | Common Stock | Conversion | Acquire C | Yes | No | 0 | 491,853 | 0.00 | 506,377 |
8 Apr 24 | Elizabeth Hoge | Common Stock | Conversion | Acquire C | Yes | No | 0 | 2,926,764 | 0.00 | 3,036,887 |
8 Apr 24 | Elizabeth Hoge | Series A Non-Voting Convertible Preferred Stock Common Stock | Conversion | Dispose C | Yes | No | 0 | 14,755.609 | 0.00 | 0 |
8 Apr 24 | Elizabeth Hoge | Series A Non-Voting Convertible Preferred Stock Common Stock | Conversion | Dispose C | Yes | No | 0 | 87,802.95 | 0.00 | 101,953.444 |
8 Apr 24 | Metin Kurtoglu | Stock Option Common Stock | Option exercise | Acquire M | No | No | 3.23 | 14,254 | 46.04 k | 14,254 |
8 Apr 24 | Metin Kurtoglu | Stock Option Series A Non-Voting Convertible Preferred Stock | Option exercise | Dispose M | No | No | 107.59 | 427.646 | 46.01 k | 0 |
8 Apr 24 | Metin Kurtoglu | Stock Option Common Stock | Option exercise | Acquire M | No | No | 3.23 | 14,254 | 46.04 k | 14,254 |
8 Apr 24 | Metin Kurtoglu | Stock Option Series A Non-Voting Convertible Preferred Stock | Option exercise | Dispose M | No | No | 107.59 | 427.645 | 46.01 k | 0 |
8 Apr 24 | Metin Kurtoglu | Stock Option Common Stock | Option exercise | Acquire M | No | No | 1.41 | 213,820 | 301.49 k | 213,820 |
8 Apr 24 | Metin Kurtoglu | Stock Option Series A Non-Voting Convertible Preferred Stock | Option exercise | Dispose M | No | No | 46.77 | 6,414.682 | 300.01 k | 0 |
News
Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
23 Apr 24
HC Wainwright & Co. Maintains Buy on Cartesian Therapeutics, Adjusts Price Target To $54
23 Apr 24
Leerink Partners Initiates Coverage On Cartesian Therapeutics with Outperform Rating, Announces Price Target of $39
23 Apr 24
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
16 Apr 24
12 Health Care Stocks Moving In Monday's Pre-Market Session
15 Apr 24
Press releases
Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
4 Apr 24
Cartesian Therapeutics Announces New Employment Inducement Grants
4 Apr 24
Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
7 Mar 24
Cartesian Therapeutics Announces New Employment Inducement Grant
5 Mar 24
Cartesian Therapeutics Announces New Employment Inducement Grants
5 Feb 24